LLLT Treatment of Lung Inflammation in COVID-19

Low-Level Laser Therapy Treatment of Lung Inflammation in COVID-19 Patients

To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.

This clinical trial is a blinded before and after comparison of the effect on patients treated with a red-light LLLT therapy for acute lung inflammation as a result of COVID-19 infection. Patients are enrolled to undergo LLLT therapy in addition to all standard ongoing therapies for COVID-19.

Outcomes for patients receiving LLLT in addition to their standard care (the treatment group) are compared to the group receiving only standard therapy for COVID-19 (control group). Effects of LLLT treatment are measured immediately following treatment, and outcome measurements are compared to the pre-treatment baseline.

Inclusion Criteria:

• Participant is diagnosed with COVID-19.
• Study participant is 18 years of age or older.
• Patient exhibiting moderate-to-acute respiratory distress.

Exclusion Criteria:

• Photosensitive condition or medication.
• Active chemotherapy treatment or other cancer treatment.
• Autoimmune Disorder.
• Pregnant, possibly pregnant or planning pregnancy prior to the end of study participation.
• Developmental disability or cognitive impairment that, in the opinion of the investigator, would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements.